October 26, 2026

Terrebonne General Health System announced the addition of Christopher Merrill, MD, hospital medicine physician, to its medical staff.

Merrill graduated from the University of Southern Mississippi in Hattiesburg, Miss., where he received a Bachelor of Science in Nursing and then went on to the University of New Orleans for pre-medicine. He earned a Doctor of Medicine from LSU Health Science Center in New Orleans.

October 26, 2026

Terrebonne General | Mary Bird Perkins Cancer Center’s Live Well Bayou, a free early detection and education event, will be held on Nov. 7 from 9 a.m. – 1 p.m. at Terrebonne General Health System (8200 Main Street, Houma) in the Drive-Thru Center Parking area. This community event will provide residents from Terrebonne Parish and surrounding communities an opportunity to take advantage of four different types of cancer screenings, including breast, prostate, colorectal, and skin cancer.

October 21, 2026

Xavier Ochsner College of Medicine has received preliminary accreditation from the Liaison Committee on Medical Education (LCME), the accrediting body for U.S. programs granting medical doctorate degrees. With this milestone, the College of Medicine will begin recruiting students in coming weeks for its inaugural class of 2027.

October 21, 2026

The Louisiana Department of Health (LDH) is accepting applications for the third round of the Health Care Employment Reinvestment Opportunity (H.E.R.O.) Fund, which provides matching grants to help expand Louisiana's health care workforce. Applications are due by 5 p.m. CT on November 19, 2026.

October 21, 2026

The Louisiana Department of Health (LDH) has issued an emergency rule adding three substances related to 7-hydroxymitragynine and mitragynine to Schedule I of Louisiana’s controlled dangerous substances list.

LDH Secretary Bruce D. Greenstein determined that placing the substances on Schedule I by emergency rule was necessary to avoid an imminent peril to the public health, safety, or welfare. Preclinical evidence indicates the substances are potent mu-opioid receptor agonists that carry risks associated with other opioid agonists, including dependence and respiratory depression.